Evoke Pharma PE Ratio 2012-2024 | EVOK
Current and historical p/e ratio for Evoke Pharma (EVOK) from 2012 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evoke Pharma PE ratio as of November 20, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Evoke Pharma PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-11-19 |
4.70 |
|
0.00 |
| 2024-09-30 |
4.76 |
$-10.99 |
0.00 |
| 2024-06-30 |
6.35 |
$-16.18 |
0.00 |
| 2024-03-31 |
7.32 |
$-21.97 |
0.00 |
| 2023-12-31 |
12.60 |
$-27.97 |
0.00 |
| 2023-09-30 |
16.56 |
$-27.25 |
0.00 |
| 2023-06-30 |
19.80 |
$-28.33 |
0.00 |
| 2023-03-31 |
22.80 |
$-30.13 |
0.00 |
| 2022-12-31 |
32.16 |
$-32.18 |
0.00 |
| 2022-09-30 |
22.44 |
$-33.02 |
0.00 |
| 2022-06-30 |
38.88 |
$-34.46 |
0.00 |
| 2022-03-31 |
71.28 |
$-36.03 |
0.00 |
| 2021-12-31 |
79.20 |
$-37.47 |
0.00 |
| 2021-09-30 |
187.20 |
$-43.23 |
0.00 |
| 2021-06-30 |
197.28 |
$-46.12 |
0.00 |
| 2021-03-31 |
263.52 |
$-76.38 |
0.00 |
| 2020-12-31 |
371.52 |
$-74.94 |
0.00 |
| 2020-09-30 |
675.36 |
$-70.62 |
0.00 |
| 2020-06-30 |
509.76 |
$-69.17 |
0.00 |
| 2020-03-31 |
167.04 |
$-41.79 |
0.00 |
| 2019-12-31 |
233.28 |
$-47.56 |
0.00 |
| 2019-09-30 |
123.84 |
$-53.32 |
0.00 |
| 2019-06-30 |
90.00 |
$-63.41 |
0.00 |
| 2019-03-31 |
216.00 |
$-69.18 |
0.00 |
| 2018-12-31 |
357.12 |
$-63.41 |
0.00 |
| 2018-06-30 |
360.00 |
$-98.00 |
0.00 |
| 2018-03-31 |
299.52 |
$-105.20 |
0.00 |
| 2017-12-31 |
325.44 |
$-139.79 |
0.00 |
| 2017-09-30 |
480.96 |
$-147.00 |
0.00 |
| 2017-06-30 |
368.44 |
$-139.79 |
0.00 |
| 2017-03-31 |
446.40 |
$-171.50 |
0.00 |
| 2016-12-31 |
290.88 |
$-183.03 |
0.00 |
| 2016-09-30 |
325.44 |
$-219.06 |
0.00 |
| 2016-06-30 |
986.40 |
$-237.79 |
0.00 |
| 2016-03-31 |
732.96 |
$-253.64 |
0.00 |
| 2015-12-31 |
475.20 |
$-272.38 |
0.00 |
| 2015-09-30 |
419.04 |
$-288.23 |
0.00 |
| 2015-06-30 |
753.12 |
$-318.50 |
0.00 |
| 2015-03-31 |
1015.20 |
$-328.58 |
0.00 |
| 2014-12-31 |
849.60 |
$-315.61 |
0.00 |
| 2014-09-30 |
791.93 |
$-285.35 |
0.00 |
| 2014-06-30 |
1164.96 |
$-253.64 |
0.00 |
| 2014-03-31 |
1206.72 |
$-181.58 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
